Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a 24-week, one arm, open-label, interventional, non-comparative multicenter study to
evaluate lipid changes in HIV infected women with hyperlipidemia on boosted PI based regimen
after switching their boosted PI to raltegravir at standard dosage with 400mg twice daily.
This study aims to study the effect on metabolic profiles by switching hyperlipidemic HIV
infected women from a PI based regimen to raltegravir.
Phase:
Phase 2
Details
Lead Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
HIV Protease Inhibitors Protease Inhibitors Raltegravir Potassium